Traders Purchase Large Volume of Spero Therapeutics Call Options (NASDAQ:SPRO)

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) saw some unusual options trading activity on Wednesday. Traders purchased 1,962 call options on the company. This represents an increase of 3,988% compared to the typical daily volume of 48 call options.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Prudential Financial Inc. bought a new stake in shares of Spero Therapeutics during the 4th quarter worth approximately $51,000. Virtu Financial LLC acquired a new position in Spero Therapeutics during the fourth quarter worth $47,000. Renaissance Technologies LLC raised its position in Spero Therapeutics by 13.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,105,591 shares of the company's stock worth $1,139,000 after acquiring an additional 130,938 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Spero Therapeutics by 26,011.9% in the fourth quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company's stock valued at $63,000 after acquiring an additional 61,388 shares during the last quarter. Finally, ADAR1 Capital Management LLC lifted its stake in Spero Therapeutics by 7.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 801,277 shares of the company's stock valued at $825,000 after acquiring an additional 57,818 shares during the last quarter. 25.60% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Stock Up 21.1%

Shares of SPRO stock traded up $0.45 during trading on Friday, reaching $2.58. The company's stock had a trading volume of 24,287,459 shares, compared to its average volume of 1,045,774. Spero Therapeutics has a one year low of $0.51 and a one year high of $2.80. The business has a fifty day moving average price of $0.77 and a 200-day moving average price of $0.88. The company has a market cap of $144.25 million, a price-to-earnings ratio of 36.86 and a beta of 0.23.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.30. The firm had revenue of $5.87 million for the quarter, compared to analysts' expectations of $11.00 million. Spero Therapeutics had a net margin of 3.30% and a return on equity of 4.03%. Research analysts anticipate that Spero Therapeutics will post -1.2 EPS for the current year.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.